Targets › CASP3
1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Apr 2028.
Thiol protease that acts as a major effector caspase involved in the execution phase of apoptosis. Following cleavage and activation by initiator caspases (CASP8, CASP9 and/or CASP10), mediates execution of apoptosis by catalyzing cleavage of many proteins. (UniProt, P42574)
Open in Phaseline: the race on CASP3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tongji Hospital | KD01 Conditionally replicative recombinant adenovirus with E3 region replaced by tBid apoptotic | CASP3 | Phase 1 | Cervical Cancer; Bladder Cancer (BC) | Apr 2028 |
Cervical Cancer (1) Bladder Cancer (BC) (1)
other (1)
Tongji Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.